Konruns(SH:603590) Zheng Quan Zhi Xing·2025-07-14 16:28Core Viewpoint - The announcement from Beijing Kangchen Pharmaceutical Co., Ltd. highlights the recent abnormal fluctuations in its stock price and reassures investors about the company's stable operational status while urging caution in trading activities [1][2]. Group 1: Production and Operational Status - The company confirms that its production and operational activities are normal, with no significant changes or undisclosed major events apart from previously disclosed information [1]. Group 2: Stock Market Trading Risks - The company's stock experienced a cumulative price increase deviation of over 20% across three consecutive trading days (July 9, 10, and 11, 2025), indicating abnormal trading activity [1]. - On July 14, 2025, the company's stock hit the daily limit up again, reflecting significant short-term price increases, prompting a warning for investors to be mindful of trading risks [1]. Group 3: Other Risks and Developments - The company has secured exclusive rights for clinical development and commercialization of Ensifentrine (Ohtuvayre™) in Greater China, a novel drug for treating chronic obstructive pulmonary disease (COPD) [2]. - Merck announced the acquisition of Verona Pharma for approximately $10 billion on July 9, 2025, which may impact the market landscape [2]. - The company's subsidiary holds a 4.96% stake in Nuance Biotech, which has not been profitable in the past five years, indicating that this investment is unlikely to significantly affect the company's overall performance [2].